Rhythm Pharmaceuticals Announces Board Changes

Kim Popovits appointed as new Director, Ed Mathers to depart

Apr. 6, 2026 at 1:26am

Got story updates? Submit your updates here. ›

Rhythm Pharmaceuticals, a global biopharmaceutical company focused on rare neuroendocrine diseases, announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers.

Why it matters

The changes to Rhythm's board reflect the company's focus on advancing its mission and long-term growth, with Popovits bringing decades of leadership experience in commercialization, reimbursement and governance to support the company's transformative work.

The details

Rhythm appointed Kim Popovits, an accomplished life sciences leader with over 40 years of experience building and leading innovative healthcare companies, as a new Director. Popovits previously served as Chairman, CEO and President of Genomic Health, where she led the development and commercialization of Oncotype DX. Meanwhile, Ed Mathers, who has served on Rhythm's board since 2013, will be departing.

  • Rhythm announced the board changes on April 3, 2026.

The players

Kim Popovits

An accomplished life sciences leader with more than 40 years of experience building and leading innovative healthcare companies. She previously served as Chairman of the Board, Chief Executive Officer and President of Genomic Health.

Ed Mathers

Has served on Rhythm's board since 2013, providing deep biopharmaceutical experience, long-term strategic perspective and steady stewardship during the company's evolution.

David Meeker, M.D.

Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“We are thrilled to welcome Kim to our Board of Directors. Kim brings decades of leadership experience across biotechnology, diagnostics and commercial innovation, with a proven track record of building high-performing organizations and bringing transformative products to patients. Her deep expertise in commercialization, reimbursement and governance will be highly valuable as we continue to advance Rhythm's mission and long-term growth.”

— David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals

“On behalf of the Board and the entire Rhythm team, I thank Ed for his many years of dedicated service and leadership. Since 2013, Ed's deep biopharmaceutical experience, long-term strategic perspective and his steady stewardship have been invaluable to Rhythm's evolution.”

— David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals

The takeaway

The addition of Kim Popovits to Rhythm's board, with her extensive experience in commercializing innovative healthcare products, signals the company's commitment to advancing its mission and driving long-term growth as it continues to transform the lives of patients living with rare neuroendocrine diseases.